Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.

Yixin ZhouChen ChenXuanye ZhangSha FuCong XueYuxiang MaWenfeng FangYunpeng YangXue HouYan HuangHongyun ZhaoShaodong HongLi Zhang

Published in: Journal for immunotherapy of cancer (2018)

PD-1/PD-L1 inhibitor plus chemotherapy, compared with chemotherapy, is associated with significantly improved PFS, ORR, and OS in first-line therapy in NSCLC, at the expense of increased treatment-related AEs.

Keyphrases

locally advanced
small cell lung cancer
squamous cell carcinoma
rectal cancer
chemotherapy induced
single cell
stem cells
radiation therapy
smoking cessation
epidermal growth factor receptor